NUCANA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.99 USD | +5.70% |
|
-10.34% | -46.04% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 750K | Capitalization | 8.36M |
|---|---|---|---|---|---|
| Net income 2024 * | -30M | Net income 2025 * | -32M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.1 x |
| P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-0.31
x | Employees | 27 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.73% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +5.70% | ||
| 1 week | -10.34% | ||
| Current month | -38.62% | ||
| 1 month | -47.52% | ||
| 3 months | -46.08% | ||
| 6 months | -71.86% | ||
| Current year | -46.04% |
1 week
3.40
4.40
1 month
3.408.08
Current year
3.4019.41
1 year
3.4023.75
3 years
3.40115.50
5 years
3.40425.00
10 years
3.40800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hugh Griffith
FOU | Founder | 56 | 97-01-27 |
Donald Munoz
DFI | Director of Finance/CFO | 56 | 15-09-30 |
Michelle Myers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hugh Griffith
FOU | Founder | 56 | 97-01-27 |
Andrew Kay
CHM | Chairman | 69 | 20-12-20 |
Adam George
BRD | Director/Board Member | 54 | 18-04-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 3.99 | +5.70% | 50,844 |
| 24-04-19 | 3.775 | -0.40% | 32,622 |
| 24-04-18 | 3.79 | -4.53% | 89,717 |
| 24-04-17 | 3.97 | +1.79% | 108,192 |
| 24-04-16 | 3.9 | -12.36% | 121,583 |
Delayed Quote Nasdaq, April 22, 2024 at 04:30 pm EDT
More quotes
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3â-deoxyadenosine (3â-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Companyâs subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.99
USD
Average target price
119.8
USD
Spread / Average Target
+2,903.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.04% | 8.36M | |
| +2.49% | 96.73B | |
| -0.32% | 21.31B | |
| -16.61% | 21.21B | |
| -4.92% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- NCNA Stock
